Johnson & Johnson : 2023 Third-Quarter Press Release & Supplemental Schedules -October 17, 2023 at 06:45 am EDT

Media contact:




Investor contact:




...

Related Keywords

Joaquin Duato ,Tesia Williams ,Jessica Moore ,European Medicines Agency Seeking Approval ,Exchange Commission ,Drug Administration Seeking ,European Academy Of Dermatology ,Finalizes Separation Of Kenvue Inc ,Johnson Announces Final Results Of Exchange ,Janssen Highlights Latest Research ,Consumer Health Company ,Trueref Technology For Mapping ,Nipocalimab Clinical Development Program To Address Unmet ,Consumer Health ,Interventional Solutions ,Johnson ,Abiomed ,Janssen To Highlight Latest Research ,European Society Of Retina Specialists ,European Commission Approves ,European Medicines Agency ,Company Consumer Health ,Chief Executive ,Innovative Medicine ,Operational Sales ,Net Earnings ,Infectious Diseases ,General Surgery ,New Announcements ,Current Reports ,Quarterly Reports ,Annual Reports ,Investor Relations ,Multiple Atrial Fibrillation Ablation Products ,First In Class Bispecific Therapy ,Heavily Pretreated Multiple Myeloma ,Novel Bispecific Therapy ,Refractory Multiple Myeloma ,Commission Approves Reduced Dosing Frequency ,Bispecific Antibody ,Submits Application ,First Line Treatment ,Adult Patients ,Advanced Non Small Cell ,Submits Supplemental New Drug Application ,Drug Administration Seeking Full ,Locally Advanced ,Submits Marketing Authorisation Application ,Metastatic Urothelial Cancer ,Abiraterone Acetate ,First And Only Dual Action Tablet ,Highlight Latest Research ,Nipocalimab Clinical Development Program ,Address Unmet ,Myasthenia Gravis ,Define New Standards ,Solid Tumor Cancers ,Severely Active Crohn ,Highlights Latest Research ,Investigational Targeted Oral Peptide ,Isevere Plaque Psoriasis ,European Academy ,Meets Primary Endpoint Resulting ,Statistically Significant ,Meaningful Improvement ,Progression Free Survival ,Versus Osimertinib ,Mutatednon Small Cell Lung Cancer ,Meets Dual Primary Endpoint Resulting ,Cell Lung Cancer ,Disease Progression ,Free Survival ,Previously Treated ,Mutated Advanced Non Small Cell Lung ,Highlight Latest Advances ,Retina Portfolio ,European Society ,Retina Specialists ,Webster Launches ,Johnson Announces Final Results ,Exchange Offer ,Finalizes Separation ,Johnson Announces Updated Financials ,Following Completion ,Johnson Marks New Era ,Global Healthcare Company ,Updated Visual Identity ,Reported Sales ,Shares Outstanding ,Euro Average Rate ,Average Shares Outstanding ,Financial Measures ,Investors Concerning Forward Looking Statements ,Private Securities Litigation Reform Act ,New Consumer Health Company ,Annual Report ,Note Regarding Forward Looking ,Markets ,